Bromocriptine
Research News and Information

Monday, November 23, 2009

[Treatment of pituitary adenomas]

25 Sep 2009 According to epidemiological studies, the prevalence of pituitary adenomas is 16.5% and the majority of them are "incidentalomas". The symptoms of pituitary disorders are often non-specific; disturbances of pituitary function, compression symptoms, ... Read more...

Bromocriptine induces parapoptosis as the main type of cell death responsible for experimental pituitary tumor shrinkage.

8 Jul 2009 Bromocriptine (Bc) produces pituitary tumoral mass regression which induces the cellular death that was classically described as apoptosis. However, recent works have related that other mechanisms of cell death could also be involved in the ... Read more...

Serotonergic and dopaminergic modulation of gambling behavior as assessed using a novel rat gambling task.

15 Jun 2009 Pathological gambling (PG) is characterized by persistent, maladaptive gambling behavior, which disrupts personal and professional life. Animal models of gambling behavior could make a significant contribution to improving our understanding of the ... Read more...

Latest indexed articles for 'Bromocriptine'

These are the very latest articles for this heading:

• [Treatment of pituitary adenomas] 25 Sep 2009
• Bromocriptine induces parapoptosis as the main type of cell death responsible for experimental pituitary tumor shrinkage. 8 Jul 2009
• Serotonergic and dopaminergic modulation of gambling behavior as assessed using a novel rat gambling task. 15 Jun 2009
• Effects of prolactin deficiency during the early postnatal period on the development of maternal behavior in female rats: mother's milk makes the difference. 14 Jun 2009
• Agonist or levodopa for Parkinson disease? Ultimately, it doesn't matter; neither is good enough. 14 Jun 2009
• Chronic lymphocytic leukemia: long-lasting remission with combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH. 30 May 2009
• Prolactin induces phosphorylation of the STAT5 in adrenal glands of Hatano rats during stress. 26 May 2009
• Evidence for a noradrenergic mechanism causing hypertension and abnormal glucose metabolism in rats with relative deficiency of gamma-melanocyte-stimulating hormone. 6 May 2009
• Rab3B immunoexpression in human pituitary adenomas. 29 Apr 2009
• Polycystic ovary syndrome and prolactinoma association. 13 Apr 2009
• Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy. 30 Mar 2009
• The role of bromocriptine in peripartum cardiomyopathy. 21 Mar 2009
• Silymarin BIO-C, an extract from Silybum marianum fruits, induces hyperprolactinemia in intact female rats. 18 Mar 2009
• Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan. 12 Mar 2009
• Correspondence (letter to the editor): Case numbers are tiny. 11 Mar 2009
• Dopamine agonists and hyperprolactinaemia. Mar 2009
• Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine. 27 Feb 2009
• Antioxidant effects of some drugs on ethanol-induced ulcers. 16 Feb 2009
• Bromocriptine use and the risk of valvular heart disease. 13 Feb 2009
• Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration. 2 Feb 2009

See a longer list of these articles.

Technical information about 'Bromocriptine'

Definition: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.

Chemical name: Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)-

Registry Number: 25614-03-3

Descriptor UI: D001971

Alternative terms: Bromocriptine; 2-Bromo-alpha-ergokryptine; 2 Bromo alpha ergokryptine; Bromocryptin; 2-Bromoergokryptine; 2 Bromoergokryptine; Bromocriptin; 2-Bromoergocryptine; 2 Bromoergocryptine; 2-Bromo-alpha-ergocryptine; 2 Bromo alpha ergocryptine; 2-Bromoergocryptine Mesylate; 2 Bromoergocryptine Mesylate; Mesylate, 2-Bromoergocryptine; Bromocriptine Mesylate; Mesylate, Bromocriptine; 2-Bromoergocryptine Methanesulfonate; 2 Bromoergocryptine Methanesulfonate; Methanesulfonate, 2-Bromoergocryptine; CB-154; CB 154; CB154; Parlodel;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antiparkinson Agents; Hormone Antagonists; Dopamine Agonists;

Tree Number: D03.132.327.412.100; D03.549.439.131; D03.549.562.100;

Online Note: use BROMOCRIPTINE to search 2-BROMOERGOCRYPTINE 1975-80

History Note: 81; was 2-BROMOERGOCRYPTINE 1978-80, was 2-BROMOERGOCRYPTINE see under ERGOTOXINE 1977, was 2-BROMOERGOCRYPTINE see under ERGOLINES 1975-76